HK1048513B - Tauopathies的诊断方法 - Google Patents

Tauopathies的诊断方法 Download PDF

Info

Publication number: HK1048513B
Authority: HK; Hong Kong
Prior art keywords: tau; phospho; tauopathy; ratio; disease
Prior art date: 2000-01-24

Application number

HK02108310.4A

Other languages

German (de)

English (en)

French (fr)

Other versions

HK1048513A1 (zh

Inventor

Eugeen Vanmechelen

Hugo Vanderstichele

Original Assignee

Fujirebio Europe N.V.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-01-24

Filing date

2001-01-18

Publication date

2007-12-07

2001-01-18 Application filed by Fujirebio Europe N.V. filed Critical Fujirebio Europe N.V.

2003-04-04 Publication of HK1048513A1 publication Critical patent/HK1048513A1/zh

2007-12-07 Publication of HK1048513B publication Critical patent/HK1048513B/zh

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Neurology (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Urology & Nephrology (AREA)
Neurosurgery (AREA)
Biochemistry (AREA)
Immunology (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Animal Behavior & Ethology (AREA)
Cell Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Toxicology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Biotechnology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Peptides Or Proteins (AREA)

HK02108310.4A 2000-01-24 2001-01-18 Tauopathies的诊断方法 HK1048513B (zh)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
EP00870008		2000-01-24
EP00870008		2000-01-24
US17839100P	2000-01-27	2000-01-27
US178391P		2000-01-27
EP00870280		2000-11-22
EP00870280		2000-11-22
PCT/EP2001/000560 WO2001055725A2 (en)	2000-01-24	2001-01-18	Diagnosis of tauopathies determining tau/phospho-tau ratio

Publications (2)

Publication Number	Publication Date
HK1048513A1 HK1048513A1 (zh)	2003-04-04
HK1048513B true HK1048513B (zh)	2007-12-07

Family

ID=27223742

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK02108310.4A HK1048513B (zh)	2000-01-24	2001-01-18	Tauopathies的诊断方法

Country Status (13)

Country	Link
US (2)	US6680173B2 (zh)
EP (1)	EP1250600B1 (zh)
JP (1)	JP5247963B2 (zh)
AT (1)	ATE342509T1 (zh)
AU (1)	AU777837B2 (zh)
BR (1)	BR0107851A (zh)
CA (1)	CA2397991C (zh)
CY (1)	CY1107993T1 (zh)
DE (2)	DE1250600T1 (zh)
DK (1)	DK1250600T3 (zh)
ES (1)	ES2274869T3 (zh)
HK (1)	HK1048513B (zh)
WO (1)	WO2001055725A2 (zh)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030162230A1 (en)	2000-09-27	2003-08-28	Reagan Kevin J.	Method for quantifying phosphokinase activity on proteins
JP4681175B2 (ja) *	2001-09-28	2011-05-11	三菱化学メディエンス株式会社	播種性血管内凝固症候群及びその発症前段階を検出する方法
AU2003257850A1 (en) *	2002-08-14	2004-03-03	Mitsubishi Kagaku Iatron, Inc.	ANTIBODY SPECIFIC TO CENTRAL Tau-PROTEIN
US20060211063A1 (en) *	2003-03-12	2006-09-21	Assay Designs Inc.	Phosphokinase assay
US7619059B2 (en) *	2003-07-29	2009-11-17	Life Technologies Corporation	Bimolecular optical probes
CA2445420A1 (en) *	2003-07-29	2005-01-29	Invitrogen Corporation	Kinase and phosphatase assays
US7727752B2 (en) *	2003-07-29	2010-06-01	Life Technologies Corporation	Kinase and phosphatase assays
WO2005080986A1 (en) *	2004-02-18	2005-09-01	University Of Iowa Research Foundation	Antibodies to phosphorylated tau, methods of making and methods of use
JP4730584B2 (ja)	2004-12-06	2011-07-20	東亞合成株式会社	抗菌ペプチド及びその利用
WO2007068105A1 (en) *	2005-12-12	2007-06-21	Robarts Research Institute	Method of diagnosing amyotrophic lateral sclerosis
CA2725143A1 (en) *	2008-05-21	2009-11-26	Neurotez, Inc.	Methods for treating progressive cognitive disorders related to neurofibrillary tangles
BR112012008381A2 (pt) *	2009-09-24	2017-06-13	Inserm (Institut Nat De La Santé Et De La Rech Médicale)	interação fkbp52-tau como novo alvo terapêutico para tratar os distúrbios neurológicos envolvendo disfunção da tau
US20130095492A1 (en) *	2010-03-05	2013-04-18	Albert Einstein College Of Medicine Of Yeshiva University	Method of detecting tau protein and tau fragments in serum
US20130052669A1 (en) *	2010-04-30	2013-02-28	Amanda G. Paulovich	Compositions and methods for reliably detecting and/or measuring the amount of a modified target protein in a sample
EP2670434B1 (en) *	2011-01-31	2018-12-26	Tau Bio-Logic Corp.	Treatment of tauopathies
WO2012142301A2 (en)	2011-04-12	2012-10-18	Quanterix Corporation	Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
GB201111361D0 (en)	2011-07-04	2011-08-17	Nordic Bioscience As	Biochemical markers for neurodegenerative conditions
CA2882034C (en)	2012-08-16	2019-10-29	Ipierian, Inc.	Methods of treating a tauopathy
US9618522B2 (en)	2012-09-05	2017-04-11	Emory University	Diagnostic testing in dementia and methods related thereto
US8980270B2 (en)	2013-01-18	2015-03-17	Ipierian, Inc.	Methods of treating a tauopathy
JP6446443B2 (ja)	2013-06-10	2018-12-26	アイピエリアン，インコーポレイティド	タウオパチーの処置方法
CA2932958A1 (en)	2013-12-20	2015-06-25	F. Hoffmann-La Roche Ag	Humanized anti-tau(ps422) antibodies and methods of use
CN105939722A (zh)	2014-02-14	2016-09-14	伊皮埃里安股份有限公司	Tau肽，抗Tau抗体，及其使用方法
CN106605146B (zh)	2014-04-08	2020-07-28	佛罗里达大学研究基金会有限公司	用于中枢神经系统的急性、亚急性和慢性创伤性损伤的蛋白质标志物
AR100978A1 (es)	2014-06-26	2016-11-16	Hoffmann La Roche	LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
DE102014013571A1 (de) *	2014-09-18	2016-03-24	Aj Roboscreen Gmbh	Monoklonaler Antikörper gegen humanes TAU-Protein
WO2016154522A1 (en) *	2015-03-25	2016-09-29	Stc. Unm	Immunotherapy compositions and methods for treatment of tauopathy and transgenic mouse
EP3744732B1 (en)	2015-06-24	2025-09-10	F. Hoffmann-La Roche AG	Humanized anti-tau(ps422) antibodies and methods of use
KR102033776B1 (ko) *	2017-10-31	2019-10-17	가천대학교 산학협력단	타우 단백질의 발현수준을 측정하는 제제를 포함하는 알츠하이머 중증도 진단용 조성물 및 이를 이용한 알츠하이머 중증도의 진단방법
BR112020018112A2 (pt)	2018-03-05	2020-12-22	Janssen Pharmaceutica Nv	Anticorpos anti-phf-tau e usos dos mesmos
CN113166235A (zh) *	2018-11-22	2021-07-23	富士瑞必欧株式会社	抗体偶联物
WO2020193500A1 (en) *	2019-03-28	2020-10-01	H. Lundbeck A/S	Use of a ps396 assay to diagnose tauophaties
US11155609B2 (en)	2019-04-05	2021-10-26	TauC3 Biologies Limited	Anti-TAUC3 antibodies and uses thereof
CN120559249A (zh) *	2019-05-31	2025-08-29	伊莱利利公司	靶向人tau的化合物和方法
CA3168823A1 (en) *	2020-02-05	2021-08-12	Sumitomo Pharma Co., Ltd.	Determination agent and determination method for tauopathy and dementia-related diseases
KR20240134175A (ko) *	2022-01-12	2024-09-06	지틴벤트 리미티드	샘플에서 타우(tau) 단백질 단편을 검출하기 위한 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2414092A (en) *	1991-08-01	1993-03-02	Paul H. Voorheis	Diagnostic method for alzheimer's disease
EP0673418B1 (en) *	1992-12-14	1998-05-06	N.V. Innogenetics S.A.	Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications
JPH06239899A (ja) *	1993-02-12	1994-08-30	Teijin Ltd	ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法
EP0737208B1 (en) *	1993-12-21	2006-08-02	Innogenetics N.V.	Monoclonal antibodies specific for phf-tau, hybridomas secreting them, antigen recognition by these antibodies and their applications
US6121003A (en) *	1994-07-29	2000-09-19	Innogentics N.V.	Monoclonal antibodies specific for an epitope of phosphorylated tau, and their use
WO1997034145A1 (fr) *	1996-03-13	1997-09-18	Mitsubishi Chemical Corporation	Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant
WO1999062548A1 (en) *	1998-06-01	1999-12-09	Advanced Research And Technology Institute	Methods and compositions for diagnosing tauopathies

2001
- 2001-01-18 CA CA2397991A patent/CA2397991C/en not_active Expired - Lifetime
- 2001-01-18 DE DE1250600T patent/DE1250600T1/de active Pending
- 2001-01-18 JP JP2001555812A patent/JP5247963B2/ja not_active Expired - Lifetime
- 2001-01-18 DK DK01909655T patent/DK1250600T3/da active
- 2001-01-18 HK HK02108310.4A patent/HK1048513B/zh not_active IP Right Cessation
- 2001-01-18 DE DE60123752T patent/DE60123752T2/de not_active Expired - Lifetime
- 2001-01-18 WO PCT/EP2001/000560 patent/WO2001055725A2/en not_active Ceased
- 2001-01-18 AT AT01909655T patent/ATE342509T1/de active
- 2001-01-18 EP EP01909655A patent/EP1250600B1/en not_active Expired - Lifetime
- 2001-01-18 BR BR0107851-8A patent/BR0107851A/pt not_active Application Discontinuation
- 2001-01-18 ES ES01909655T patent/ES2274869T3/es not_active Expired - Lifetime
- 2001-01-18 AU AU37319/01A patent/AU777837B2/en not_active Expired
- 2001-01-24 US US09/769,180 patent/US6680173B2/en not_active Expired - Lifetime
2003
- 2003-10-09 US US10/682,103 patent/US7387879B2/en not_active Expired - Lifetime
2007
- 2007-01-11 CY CY20071100047T patent/CY1107993T1/el unknown

Also Published As

Publication number	Publication date
DE60123752D1 (de)	2006-11-23
WO2001055725A2 (en)	2001-08-02
JP5247963B2 (ja)	2013-07-24
WO2001055725A3 (en)	2001-12-20
AU3731901A (en)	2001-08-07
CA2397991A1 (en)	2001-08-02
AU777837B2 (en)	2004-11-04
DK1250600T3 (da)	2007-02-05
ES2274869T3 (es)	2007-06-01
CY1107993T1 (el)	2013-09-04
US7387879B2 (en)	2008-06-17
US6680173B2 (en)	2004-01-20
ATE342509T1 (de)	2006-11-15
CA2397991C (en)	2017-10-24
EP1250600B1 (en)	2006-10-11
HK1048513A1 (zh)	2003-04-04
US20030194742A1 (en)	2003-10-16
EP1250600A2 (en)	2002-10-23
DE1250600T1 (de)	2003-03-06
DE60123752T2 (de)	2007-08-23
BR0107851A (pt)	2002-10-29
US20040091942A1 (en)	2004-05-13
JP2003521499A (ja)	2003-07-15

Publication	Publication Date	Title
EP1250600B1 (en)	2006-10-11	Diagnosis of tauopathies determining tau/phospho-tau ratio
Sjögren et al.	2001	Both total and phosphorylated tau are increased in Alzheimer's disease
Skoog et al.	1995	A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele
Blennow et al.	1995	Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?
CN106574930B (zh)	2019-09-03	评价脑内的淀粉样蛋白β肽蓄积状态的替代性生物标记物和其分析方法
US6670137B2 (en)	2003-12-30	Differential diagnosis of neurological diseases
US5601985A (en)	1997-02-11	Method of detecting abnormally phosphorylated tau(τ)
JP6129868B2 (ja)	2017-05-17	アルツハイマー病を診断するための方法
Rosen et al.	2010	Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer’s disease
US20100041060A1 (en)	2010-02-18	Iron-regulating protein-2(irp-2) as a diagnostic for neurodegenerative disease
Frölich et al.	1991	Integrity of the blood-CSF barrier in dementia of Alzheimer type: CSF/serum ratios of albumin and IgG
WO2013059786A1 (en)	2013-04-25	Methylated peptides derived from tau protein and their antibodies for diagnosis and therapy of alzheimer's disease
JP2004532633A (ja)	2004-10-28	進行性の慢性痴呆疾患の検出方法、これに適したペプチド及び検出試薬
Yamada et al.	1994	Increased concentration of C4d complement protein in the cerebrospinal fluids in progressive supranuclear palsy
JP2005132738A (ja)	2005-05-26	アルツハイマー病のタンパク質分子レベルにおける検出方法
JP4851052B2 (ja)	2012-01-11	神経学的疾患の分別診断
PT1250600E (pt)	2007-01-31	Diagnóstico de taupatias a partir da determinação da razão tau/fosfo-tau
Mehta	2018	Amyloid beta and tau proteins in
Mehta	2018	Amyloid beta and tau proteins in Alzheimer’s disease and Down syndrome
Amberla et al.	1996	669 Tau levels in CSF are related to cognitive functions in familial Alzheimer's disease
KR20240002809A (ko)	2024-01-08	타우 단백질 유래 인산화 펩타이드를 이용한 알츠하이머병 조기 진단, 단계 구분 및 뇌의 아밀로이드 베타 축적 판별 방법
Stratification	0	The Amyloid Beta-42/40-Ratio
AU2008202723A1 (en)	2008-07-10	Iron Regulating Protein-2 (IRP-2) as a Diagnostic For Neurodegenerative Disease

Legal Events

Date	Code	Title	Description
2017-08-11	PC	Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)	Effective date: 20170118